The association between the NT-pro-BNP/eGFR ratio and coronary artery disease severity in Non-ST elevation myocardial infarction
Irish Journal of Medical Science, cilt.195, sa.4, ss.1923-1930, 2026 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 195 Sayı: 4
- Basım Tarihi: 2026
- Doi Numarası: 10.1007/s11845-026-04332-z
- Dergi Adı: Irish Journal of Medical Science
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE
- Sayfa Sayıları: ss.1923-1930
- Anahtar Kelimeler: coronary artery disease, glomerular filtration rate, Myocardial Infarction, N-terminal pro-brain natriuretic peptide, Non-ST Elevation
- Ankara Yıldırım Beyazıt Üniversitesi Adresli: Evet
Özet
Background: While eGFR indicates renal function and NT-pro-BNP aids cardiovascular risk assessment, the prognostic value of their ratio (NT-pro-BNP/eGFR) in non-ST elevation myocardial infarction (NSTEMI) appears to be modest. Aims: This study aimed to investigate the relationship between the NT-pro-BNP/eGFR ratio and the severity of angiographically confirmed CAD in NSTEMI patients. Methods: This retrospective analysis encompassed 802 patients diagnosed with NSTEMI who received coronary angiography. NT-pro-BNP levels were measured within the first 6 h of admission to minimize variability resulting from post-ischemic elevation. The severity of CAD was assessed using the SYNTAX score. ROC curve analysis was used to assess the predictive utility of the NT-pro-BNP/eGFR ratio. Results: Patients with SYNTAX scores ≥ 23 (n = 248) had significantly higher NT-pro-BNP/eGFR ratios than those with < 23 (n = 554) (34.56 [16.4–68.1] vs. 19.50 [9.2–33.3]; p < 0.001). A cut-off ≥ 25.54 predicted high SYNTAX scores with 60% sensitivity and 58% specificity (AUC = 0.621; 95% CI: 0.587–0.655; p < 0.001). The ratio remained an independent predictor of CAD severity (OR = 1.440; 95% CI: 1.034–2.007; p = 0.031). Conclusion: In NSTEMI patients, the NT-pro-BNP/eGFR ratio is independently associated with the severity of angiographically confirmed CAD. Despite its moderate discriminative power, this low-cost and accessible biomarker may support early risk stratification and identify patients with high atherosclerotic burden who could benefit from more intensive management.